Antibody profiles in COVID‐19 convalescent plasma prepared with amotosalen/UVA pathogen reduction treatment
Transfusion2022Vol. 62(3), pp. 570–583
Citations Over TimeTop 24% of 2022 papers
Anil Bagri, Rafael Ramiro de Assis, Cheng‐ting Tsai, Graham Simmons, Zhen Mei, Melissa von Goetz, Michelle Gatmaitan, Mars Stone, Clara Di Germanio, Rachel Martinelli, Orsolya Darst, Jowin Rioveros, Peter V. Robinson, Dawn C. Ward, Alyssa Ziman, David Seftel, Saahir Khan, Michael P. Busch, Philip L. Felgner, Laurence Corash
Abstract
The findings of this study support the selection of effective CCP combined with the use of A/UVA-PRT in the production of CCP for patients with COVID-19.
Related Papers
- → Temporal maturation of neutralizing antibodies in COVID-19 convalescent individuals improves potency and breadth to circulating SARS-CoV-2 variants(2021)154 cited
- Immunologic studies of Japanese encephalitis virus in Japan. III. Infection and antibody responses of birds.(1959)
- → Role of Neutralizing Antibody in the Pathogenesis of Zoster and the Correlation of Severity with Anti‐gE: gI Antibody Response(2003)3 cited
- Activities of Serum Binding Antibody and Neutralizing Antibody on the Cynomolgus Undergoing Long-term Toxicity Study with Polyglycol Recombinant Consensus Interferon α(2010)
- Studies on the neutralizing antibody to herpes simplex virus. III. Detection of type-specific antibody by slow-reacting complement-requiring neutralizing antibody assay.(1982)